Related Experiment Videos
Corticosteroids therapy in paroxysmal nocturnal hemoglobinuria
American Journal of Hematology
|May 1, 1987
Summary
High-dose alternate-day prednisolone shows efficacy in treating paroxysmal nocturnal hemoglobinuria (PNH). While not curative, this treatment improved hemoglobin levels in some PNH patients, particularly when initiated sooner after diagnosis.
Area of Science:
- Hematology
- Internal Medicine
- Pharmacology
Background:
- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder.
- Current PNH treatments aim to manage symptoms and complications.
- High-dose corticosteroids like prednisolone have been explored for PNH management.
Purpose of the Study:
- To evaluate the efficacy of alternate-day, high-dose prednisolone for PNH treatment.
- To identify factors influencing treatment response in PNH patients.
Main Methods:
- A cohort of 19 patients with PNH received alternate-day, high-dose prednisolone.
- Patient demographics, clinical data, and hematologic parameters were analyzed.
- Response was assessed based on improvements in hemoglobin and other markers.
Main Results:
- Eleven out of 19 patients (58%) showed improvement, with 8 good and 3 fair responses.
- Responders experienced gradual hemoglobin increase, but none normalized.
- Delayed treatment initiation and older age at treatment were associated with non-response.
Conclusions:
- Alternate-day, high-dose prednisolone is an effective treatment option for some PNH patients.
- Early treatment initiation appears crucial for a favorable hematologic response.
- Further research may explore optimal prednisolone dosing and patient selection for PNH.